These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19102724)

  • 1. Payer perspectives on pharmacogenomics testing and drug development.
    Epstein RS; Frueh FW; Geren D; Hummer D; McKibbin S; O'Connor S; Randhawa G; Zelman B
    Pharmacogenomics; 2009 Jan; 10(1):149-51. PubMed ID: 19102724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic opportunities and challenges for pharmacogenomics.
    Deverka PA; Vernon J; McLeod HL
    Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop.
    Hinman L; Spear B; Tsuchihashi Z; Kelly J; Bross P; Goodsaid F; Kalush F
    Pharmacogenomics; 2009 Jan; 10(1):127-36. PubMed ID: 19102722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring the value of pharmacogenomics.
    Phillips KA; Van Bebber SL
    Nat Rev Drug Discov; 2005 Jun; 4(6):500-9. PubMed ID: 15915153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
    Lesko LJ; Zineh I
    Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
    de Leon J
    Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cost-effectiveness analysis in the era of pharmacogenomics.
    Flowers CR; Veenstra D
    Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics: history, barriers, and regulatory solutions.
    Blankstein S
    Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lag from FDA approval to published cost-utility evidence.
    Chambers JD; Thorat T; Pyo J; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic biomarkers in drug labels: what do they tell us?
    Tutton R
    Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.